Policy | October 12, 2025
AstraZeneca to lower cost of medicines for American patients
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Merck will showcase results in innovative solutions in HIV treatment and prevention
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
New study presents a human-relevant stress model for assessing potential therapeutics
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Subscribe To Our Newsletter & Stay Updated
